GraÅ¼yna E BÄdkowska

List of Publications by Year
in descending order

19	317	759233 12	888059 17
papers	citations	h-index	g-index

21	21	21	393
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. Journal of Ovarian Research, 2013, 6, 45.	3.0	49
2	Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. OncoTargets and Therapy, 2016, 9, 911.	2.0	42
3	Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer. Annals of Laboratory Medicine, 2016, 36, 223-229.	2.5	25
4	M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients. Journal of Ovarian Research, 2015, 8, 27.	3.0	22
5	Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients. Biomarkers, 2017, 22, 157-164.	1.9	22
6	Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	18
7	Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Growth Factors, 2012, 30, 357-366.	1.7	16
8	Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients. Advances in Medical Sciences, 2013, 58, 207-215.	2.1	16
9	Hematopoietic cytokines as tumor markers in gynecological malignancies: A multivariate analysis with ROC curve in endometrial cancer patients. Growth Factors, 2012, 30, 29-36.	1.7	14
10	VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve. Growth Factors, 2013, 31, 98-105.	1.7	14
11	Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers. Journal of Ovarian Research, 2017, 10, 39.	3.0	14
12	Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. Folia Histochemica Et Cytobiologica, 2012, 50, 213-219.	1.5	13
13	Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis. Cancer Control, 2018, 25, 107327481878935.	1.8	10
14	Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients â€“ ROC Analysis. Anticancer Research, 2019, 39, 2575-2582.	1.1	8
15	Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients. Clinical Laboratory, 2016, 62, 1661-1669.	0.5	7
16	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer. Journal of Clinical Medicine, 2021, 10, 5452.	2.4	7
17	Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP-2 and TIMP-2 in patients. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1579-1585.	2.0	6
18	Narrowband ultraviolet B light treatment changes plasma concentrations of MMP-3, MMP-9 and TIMP-3 in psoriatic patients. Therapeutics and Clinical Risk Management, 2017, Volume 13, 575-582.	2.0	4

#	Article	IF	Citations
19	Influence of narrowband ultraviolet-B phototherapy on plasma concentration of matrix metalloproteinase-12 in psoriatic patients. Postepy Dermatologii I Alergologii, 2017, 4, 328-333.	0.9	3